Drug Profile
Research programme: antibody therapeutics - ImmunoBrain Checkpoint
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator ImmunoBrain Checkpoint
- Class Antibodies; Antidementias
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease